Antibody treatment to deplete transthyretin amyloid deposits in the heart

Nature Reviews Cardiology, Published online: 07 June 2023; doi:10.1038/s41569-023-00899-7An antibody-based therapy for transthyretin amyloid cardiomyopathy is safe, and initial findings from a phase I trial suggest that it might deplete amyloid deposits in the heart.

Source: Nature Reviews Cardiology - June 7, 2023 Category: Cardiology Authors: Gregory B. Lim Source Type: research